Given that Rb is rarely lost in ESCC, while Fbxo4 loss or cyclin D1 amplification occurs at a high frequency, it is important to fill this knowledge gap in order to develop therapies for ESCC that may also be efficient for other tumors with dysregulation of this signaling pathway. This evidence concerns the gene RB1 and esophageal squamous cell carcinoma.